Medical Analysis

Understanding Viable CD34 Cells: Clinical Significance and Laboratory Protocols

The monitoring of CD34 count and viability following collection is a critical procedure in clinical medicine, serving to assess the quality of harvested cells and provide a reliable indication of whether the collection is sufficient for successful engraftment [12]. This vital process may be repeated until a clinically significant yield is achieved to ensure successful transplantation [13]. The CD34 marker represents an essential type of white blood cell that plays a prominent role during bone marrow transformations. Clinicians frequently perform this test to gauge the precise level of CD34 in a patient’s blood, as well as to determine the viability of potential bone marrow donors. CD34-positive (CD34+) lymphohaematopoietic stem cells are widely recognized for their unique ability to reconstitute blood cells within the hematopoietic system, a fundamental property that allows these cells to be utilized in treating humans suffering from various ischemic conditions.

Functions and Multipotency of CD34+ Hematopoietic Progenitor Cells

CD34+ hematopoietic progenitor cells (HPCs) are systematically isolated from human blood stem cells through the process of apheresis. Once successfully transplanted, these potent cells have the capability to differentiate into an extensive variety of specialized cell types. This differentiation potential includes fibroblasts, osteoblasts, chondrocytes, myocytes, adipocytes, and endothelial cells. Cell viability is defined technically as the number of healthy, functioning cells within a given sample. Furthermore, the study of cell proliferation serves as a vital indicator for researchers seeking to understand the complex mechanisms governing the action of specific genes, proteins, and molecular pathways involved in cell survival or death, particularly after exposure to toxic agents. These cells possess a unique biological trait termed multipotency, which allows them to produce a diverse array of mature blood cells, including leukocytes, erythrocytes, and platelets. Consequently, these cells are highly capable of self-generation and biological perpetuation.

Indications for Clinical CD34 Assessment

The clinical assessment of viable CD34 cells is primarily indicated for two critical purposes:

• To monitor the comprehensive quality of harvested cellular material [14].

• To provide an objective indication as to the likelihood that the specific collection is sufficient for successful patient engraftment [12].

Methods for the Accurate Estimation of Viable CD34 Cells

The estimation of viable CD34 cells relies on highly specialized laboratory techniques designed to ensure precision:

• Flow Cytometry Combined with Viability Testing: This remains a gold-standard technique for quantifying cells while simultaneously assessing their functional viability [3, 6, 8].

• Colony Forming Unit (CFU) Assays: This methodology provides a biological indication regarding the presence and potential activity of viable progenitor cells within the sample [15].

Comprehensive Sample Collection Protocols for CD34 Testing

The accuracy of results is heavily dependent on strictly adhered-to collection protocols. The following table summarizes the requirements for ensuring sample integrity:

Advanced Techniques in CD34 Cell Separation and Isolation

The isolation of CD34+ cells is performed through sophisticated immunomagnetic labeling processes [12]. The tube containing the labeled cell suspension is placed into an appropriate EasySep™ magnet. After a defined incubation period, the unwanted CD34- cells are poured off, leaving the desired, highly-enriched CD34+ cells within the tube. While this immunomagnetic approach is standard for blood-derived samples, other stem cell types require different techniques. For instance, embryonic stem cells are typically isolated from the inner cell mass of blastocysts using mechanical dissection, laser dissection, or immunosurgery, while adult stem cells derived from tissues such as bone marrow or adipose tissue necessitate techniques including clinical aspiration, harvesting, and tissue-specific dissection.

Step-by-Step Laboratory Separation of Viable CD34 Cells (EasySep™ Method)

The separation process follows a rigid, multi-stage protocol to ensure purity:

1. Antibody Addition: Add RosetteSep™ antibody cocktail to whole cord blood (CB).

2. Incubation & Layering: Incubate the mixture and layer over a specialized density gradient medium.

3. Centrifugation: Centrifuge to separate plasma, pre-enriched cells, density gradient medium, and unwanted cells (forming immunorosettes).

4. Collection: Carefully collect the pre-enriched CD34+ cells.

5. Enrichment: Add EasySep™ isolation cocktail to the pre-enriched CD34+ cells and incubate.

6. Labeling: Add EasySep™ Dextran RapidSpheres™ and incubate to finalize the labeled cell suspension.

7. Magnetic Separation: Place the tube in the EasySep™ magnet.

8. Final Harvest: Pour off the supernatant. The positively-selected CD34+ cells remain in the tube. Perform 3 or 4 additional washes, then collect the final CD34+ cells by removing the tube from the magnet.

Sample Preparation and Technical Benchmarking

To prepare the sample for analysis, perform the following steps:

1. Add Anti-CD45 FITC and Anti-CD34 PE to a 12-mm × 75-mm polystyrene tube (or use a Lyophilized counting bead tube) [6, 15].

2. Add Viability dye until reaching a final concentration of 1 µg/mL [1, 2].

3. Add 100 µL of the well-mixed cell sample to the bottom of the tube.

4. Mix the resulting mixture thoroughly.

5. Incubate for 20 minutes while ensuring the sample remains protected from light [6].

Reference Intervals for Clinical CD34 Analysis

The clinical interpretation of these results is based on established reference intervals for absolute and relative counts:

• Absolute Viable Cells: 3.50 to 66.10 cells/µL (median: 16.81 cells/µL) [1].

• Relative Counts: Reference range for CD34-positive cells is 0.09 to 0.99 (median: 0.34) [1].

Prognostic Significance and Clinical Interpretation

The presence and percentage of CD34+ cells hold significant prognostic value:

• Myelodysplastic Syndrome (MDS): An increased percentage of myeloid CD34+ bone marrow cells is associated with a better prognosis in IPSS-R myelodysplastic syndrome patients [5].

• Circulating Cells: The presence of circulating CD34+ cells serves as an adverse prognostic factor in myelodysplastic syndromes [5].

• Healthy Distribution: At a steady state in healthy donors, the percentage of CD34+ cells among total circulating nucleated cells is 0.06%, compared to 1.1% in the bone marrow. This reflects an eighteen-fold difference favoring the bone marrow as a stem cell source [12].

• Clinical Intervention: If cellular levels are found to be on the lower side, clinicians may need to mobilize hematopoietic stem cells (HSC) from the bone marrow into the peripheral blood using appropriate pharmacological agents [12].

For Non-Medicos

A Simple Guide to Understanding CD34 Blood Cell Testing

If you or a loved one have been asked to get a CD34 test, you might be wondering what this means. Simply put, CD34 is a “label” or marker found on the surface of special cells in your body called stem cells. Think of these as the “master cells” that can grow into the various parts of your blood, such as red cells, white cells, and platelets [12]. Doctors check these cells to make sure there are enough healthy ones available for treatments like bone marrow transplants [12].

Why is this test performed?

Doctors order this test for two main reasons. First, they want to check the quality of the cells that have been collected, usually from the blood or bone marrow [14]. Second, they need to know if there are enough of these healthy cells present to help a patient recover, which is a process called “engraftment” [12]. If the count is too low, the medical team might need to try again or use specific medicines to help move more of these cells from the bone marrow into the bloodstream where they are easier to collect [12].

What happens during the test?

Your doctor will take a small sample of your blood or bone marrow. It is very important that this sample is handled correctly and sent to the lab quickly [12]. Once it reaches the lab, scientists use a special magnet-based process to separate these CD34-labeled stem cells from the other, unwanted cells [12]. They then use high-tech equipment to count exactly how many of these healthy, active cells are in your sample [1, 3]. The result helps your medical team decide the next best steps for your care.

Understanding your results

Results from a CD34 test help doctors predict how well a treatment might work [12]. For example, in certain blood disorders like myelodysplastic syndromes, having the right number of these cells in the bone marrow is actually a positive sign [5]. On the other hand, finding too many of them floating in the regular bloodstream when they should be in the bone marrow can sometimes be a warning sign [5]. Your doctor will look at these numbers alongside your other tests to give you the most accurate picture of your health.

This guide is intended for informational purposes only. Always discuss your specific laboratory results and clinical care plan directly with your healthcare provider, as they understand your unique medical history.

References:

1. Yu, H., Yoo, J., Hwang, J. S., Kim, M., Bae, K. H., Jekarl, D. W., Oh, J. H., Lee, J. Y., Han, S., Chung, C., Kim, M., & Kim, Y. (2019). Enumeration of CD34-positive Stem Cells Using the ADAMII Image-based Fluorescence Cell Counter. Annals of Laboratory Medicine, 39(4), 388–395. https://doi.org/10.3343/alm.2019.39.4.388 Cited by: 7

2. Thedsawad, A. (2024). Comparison of CD34+ cell enumeration between flow cytometric analysis and ADAMII-CD34 image-based fluorescence cell counter. PLOS ONE, 19(11), e0345611. https://doi.org/10.1371/journal.pone.0345611

3. Murugesan, M., Nair, C. K., Nayanar, S. K., & Pentapati, K. C. (2019). Flow cytometric enumeration of CD34+ hematopoietic stem cells: A comparison between single- versus dual-platform methodology using the International Society of Hematotherapy and Graft Engineering protocol. Asian Journal of Transfusion Science, 13(1), 43–49. https://doi.org/10.4103/ajts.ajts_83_18 Cited by: 25

4. Huang, S., Xu, K., Xu, S., Yu, S., Miao, Y., & Wang, J. (2021). Enumeration of viable CD34+ cells in cord blood using a novel stem cell enumeration kit. Journal of International Medical Research, 49(11). https://doi.org/10.1177/03000605211055384 Cited by: 1

5. Duarte, F. B., De Jesus Dos Santos, T. E., Barbosa, M. C., Moura, A. T. G., De Vasconcelos, J. P. L., Rocha-Filho, F. D., Coutinho, D. F., Zalcberg, I., Vasconcelos, P. R. L., Garcia, Y. D. O., & Lemes, R. P. G. (2018). Presence of CD34+ in Megakaryocytes in Association With p53 Expression Predicts Unfavorable Prognosis in Low-risk Myelodysplastic Syndrome Patients. In Vivo, 33(1), 277–280. https://doi.org/10.21873/invivo.11472 Cited by: 4

6. Sutherland, D. R., Anderson, L., Keeney, M., Nayar, R., & Chin-Yee, I. (1996). The ISHAGE guidelines for CD34+ cell determination by flow cytometry. Journal of Hematotherapy, 5(3), 213–226.

7. Keeney, M., Chin-Yee, I., Weir, K., Popma, J., Blasig, R., & Sutherland, D. R. (1998). Single platform flow cytometric absolute CD34+ cell counting. Cytometry, 34(2), 61–70.

8. Barnett, D., Janossy, G., Lubenko, A., Matutes, E., Newland, A., & Reilly, J. T. (1999). Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Clinical & Laboratory Haematology, 21(5), 301–308.

9. Del Vecchio, L., Schiavone, E. M., Ferrara, F., & Soricelli, A. (2007). Standardization of CD34+ cell enumeration: a multi-center study in Italy. Cytometry Part B: Clinical Cytometry, 72(1), 6–13.

10. Whitby, A., Whitby, L., Fletcher, M., Reilly, J. T., & Barnett, D. (2000). ISHAGE protocol: an audit of CD34+ cell enumeration in UK NEQAS. Clinical & Laboratory Haematology, 22(4), 215–219.

11. Chin-Yee, I. H., Keeney, M., Anderson, L., & Sutherland, D. R. (1997). Clinical application of the ISHAGE protocol for CD34+ cell enumeration. Journal of Hematotherapy, 6(5), 457–465.

12. Hillyer, C. D., & Shaz, B. H. (2010). Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Elsevier/Academic Press.

13. Papa, S., Vitale, M., Cinti, C., Malavasi, F., & Brighenti, A. (2009). The optimization of CD34+ cell enumeration in clinical practice. Transfusion and Apheresis Science, 41(3), 195–201.

14. Armitage, S., Hargreaves, R., & Samson, D. (1999). CD34+ cell enumeration for clinical transplantation: results of the first UK NEQAS exercise. Clinical & Laboratory Haematology, 21(2), 119–123.

15. Gratama, J. W., Kraan, J., Levering, W. H., & de Vries, J. (2003). Analysis of CD34+ hematopoietic stem and progenitor cells by flow cytometry. Current Protocols in Cytometry, 6(1).

FAQ’s:

• What are CD34 cells?
  CD34 cells are special stem cells that can grow into various essential blood cells.

• Why is CD34 testing needed?
  Testing checks the quality and quantity of harvested cells to ensure successful patient transplant engraftment.

• Which samples are typically tested?
  Preferred samples include peripheral blood, bone marrow, and cord blood collected in K3EDTA tubes.

• How are these cells isolated?
  Cells are isolated using specialized immunomagnetic labeling and a magnet-based EasySep™ separation process.

• What is cell viability?
  Viability measures the number of healthy, functional cells present within a collected laboratory sample.

• Are reference ranges standard?
  Yes, clinical results are compared against established reference intervals for absolute and relative cell counts.

• Do results predict prognosis?
  Yes, CD34 levels provide significant prognostic information, especially in conditions like myelodysplastic syndrome.

• Can low counts be treated?
  Yes, clinicians can use specific medicines to mobilize stem cells from bone marrow into the blood.

• How is the sample stored?
  Samples must be refrigerated at 4°C and transported to the lab immediately for optimal results.

• Is this test for everyone?
  It is primarily used for patients undergoing stem cell transplantation or those with specific blood disorders.

Related Tests

• Immature Platelet Fractions (IPF)
• Factor VIII
• Red Blood Cells (RBCs)